| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1030095759 |
| P356 | DOI | 10.1186/AR2598 |
| P932 | PMC publication ID | 2688169 |
| P698 | PubMed publication ID | 19473554 |
| P5875 | ResearchGate publication ID | 26244920 |
| P50 | author | Georg Schett | Q73565915 |
| P2093 | author name string | Steffen Gay | |
| Oliver Distler | |||
| Christian Beyer | |||
| Jörg H W Distler | |||
| P2860 | cites work | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing | Q24291102 | ||
| C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation | Q24291783 | ||
| A conserved family of prolyl-4-hydroxylases that modify HIF | Q24291794 | ||
| Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension | Q24307473 | ||
| Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway | Q24310405 | ||
| Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. | Q24534053 | ||
| Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor | Q24536055 | ||
| The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development | Q24595910 | ||
| Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein | Q24599442 | ||
| HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia | Q24671941 | ||
| A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development | Q24681396 | ||
| Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation | Q27860876 | ||
| The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages | Q28143066 | ||
| Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation | Q28188357 | ||
| Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation | Q28216594 | ||
| Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch | Q28217194 | ||
| Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha | Q28259513 | ||
| Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor | Q28271379 | ||
| Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1 | Q28282227 | ||
| HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia | Q28300406 | ||
| HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption | Q28300415 | ||
| Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha | Q28507449 | ||
| Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death | Q28510984 | ||
| Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver | Q28575573 | ||
| Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis | Q28582038 | ||
| Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein | Q28678484 | ||
| Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 | Q29615241 | ||
| Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes | Q29617594 | ||
| Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization | Q30453942 | ||
| Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes | Q33371036 | ||
| Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism | Q73683729 | ||
| Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway | Q74485172 | ||
| A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha | Q74535979 | ||
| Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression | Q77193628 | ||
| Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1 | Q78225117 | ||
| Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis | Q80123824 | ||
| VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells | Q82264553 | ||
| Mammalian oxygen sensing, signalling and gene regulation. | Q33870583 | ||
| Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy | Q34086442 | ||
| Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression | Q34104247 | ||
| Transcription. Oxygen sensing gets a second wind | Q34520727 | ||
| Oxygen sensors and angiogenesis | Q34611016 | ||
| Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression | Q34770083 | ||
| Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition | Q35083605 | ||
| Fibrosis in scleroderma | Q35169066 | ||
| Systemic sclerosis: a prototypic multisystem fibrotic disorder | Q35649427 | ||
| Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. | Q35688102 | ||
| Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery | Q35746429 | ||
| Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure | Q36314459 | ||
| PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis | Q36534385 | ||
| Angiogenesis and vasculogenesis in systemic sclerosis | Q36599185 | ||
| Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells | Q38311709 | ||
| Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells | Q38341890 | ||
| HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels | Q38346980 | ||
| An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha | Q40088306 | ||
| Regulation of connective tissue synthesis in systemic sclerosis. | Q40468537 | ||
| The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen | Q40631949 | ||
| Systemic sclerosis. A vascular perspective | Q40922429 | ||
| Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. | Q40933142 | ||
| Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha. | Q40980305 | ||
| Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha | Q41007339 | ||
| Selection and analysis of a mutant cell line defective in the hypoxia-inducible factor-1 alpha-subunit (HIF-1alpha). Characterization of hif-1alpha-dependent and -independent hypoxia-inducible gene expression | Q41045748 | ||
| Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. | Q41094584 | ||
| Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. | Q41481649 | ||
| HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia | Q42512319 | ||
| Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. | Q43491607 | ||
| Suppression of tumor growth through disruption of hypoxia-inducible transcription | Q45872806 | ||
| Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis | Q47391889 | ||
| Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. | Q48422889 | ||
| Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. | Q51614218 | ||
| Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. | Q53594263 | ||
| Hypoxia-Inducible Factor-1 (HIF-1) | Q61645733 | ||
| Cell type-specific effect of hypoxia and platelet-derived growth factor-BB on extracellular matrix turnover and its consequences for lung remodeling. | Q64914239 | ||
| Cutaneous Hypoxia in Patients With Systemic Sclerosis (Scleroderma) | Q68500041 | ||
| Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis | Q68823103 | ||
| Beta ig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions | Q71066400 | ||
| Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension | Q71738016 | ||
| Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP | Q73042158 | ||
| Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis | Q73385986 | ||
| Expression of betaig-h3 by human bronchial smooth muscle cells: localization To the extracellular matrix and nucleus | Q73496088 | ||
| P433 | issue | 2 | |
| P921 | main subject | hypoxia | Q105688 |
| pathogenesis | Q372016 | ||
| systemic scleroderma | Q5340515 | ||
| cell hypoxia | Q71228512 | ||
| P304 | page(s) | 220 | |
| P577 | publication date | 2009-04-21 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis | |
| P478 | volume | 11 |
| Q39519878 | A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis |
| Q40423484 | Acroosteolysis in systemic sclerosis: An insight into hypoxia-related pathogenesis |
| Q35207610 | Apoptosis modulation as a promising target for treatment of systemic sclerosis |
| Q33655176 | Assessing microvascular changes in systemic sclerosis diagnosis and management |
| Q39949755 | Capillaroscopy as an Outcome Measure for Clinical Trials on the Peripheral Vasculopathy in SSc—Is It Useful? |
| Q41199736 | Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling |
| Q39822872 | Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis. |
| Q53336263 | Correlation between elastosonography and nailfold microvascular alterations in systemic sclerosis patients. |
| Q37690002 | Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis |
| Q36429810 | Dietary supplementation of some antioxidants against hypoxia. |
| Q35620315 | Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis |
| Q38625028 | Efficient therapy of ischaemic lesions with VEGF121-fibrin in an animal model of systemic sclerosis |
| Q26748338 | Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases |
| Q38022768 | Energy metabolism and rheumatic diseases: from cell to organism |
| Q37294119 | Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis |
| Q96303580 | Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients |
| Q52536468 | Human Fibrotic Diseases: Current Challenges in Fibrosis Research. |
| Q60947878 | Hydrogen Sulfide: A Therapeutic Option in Systemic Sclerosis |
| Q57132808 | Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells |
| Q37616390 | Interfacial Adipose Tissue in Systemic Sclerosis |
| Q37310583 | Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis |
| Q35112344 | Metabolomics--a novel window into inflammatory disease. |
| Q64280139 | Overexpression of ubiquitin-specific peptidase 15 in systemic sclerosis fibroblasts increases response to transforming growth factor β |
| Q48033104 | Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity? |
| Q33806149 | Oxidized low-density lipoprotein alters the effect of matrix stiffness on the formation of endothelial networks and capillary lumens. |
| Q33745028 | PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis |
| Q41313325 | Regulation of Human Macrophage M1-M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. |
| Q38105984 | Review: evidence that systemic sclerosis is a vascular disease |
| Q37224668 | Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis |
| Q91235944 | Shared and distinct mechanisms of fibrosis |
| Q58705720 | The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy |
| Q37641758 | The role of microparticles in the pathogenesis of rheumatic diseases. |
| Q92559978 | Transcriptome analysis defines myocardium gene signatures in children with ToF and ASD and reveals disease-specific molecular reprogramming in response to surgery with cardiopulmonary bypass |
| Q33531797 | Transcriptome profiles of carcinoma-in-situ and invasive non-small cell lung cancer as revealed by SAGE |
| Q40071201 | Upregulation of VEGF expression is associated with accumulation of HIF-1α in the skin of naïve scleroderma patients. |
| Q26749091 | Vascular Remodelling and Mesenchymal Transition in Systemic Sclerosis |
| Q38790174 | Vascular changes in bleomycin-induced scleroderma |
| Q82334236 | [Scleroderma] |
Search more.